Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
08/2003
08/14/2003US20030153511 Administering a dose of multiple function protein 14 (MFP 14), animal extracts from liver
08/14/2003US20030153504 Antiinflammatory agents selects from a group of tetrapeptides, hexapeptides, octapeptides, oligopeptides, polypeptides
08/14/2003US20030153503 Therapeutic treatment of hypoxia, anemia, and enzyme inhibitors; antihypoxic agents
08/14/2003US20030153081 Viral core protein-cationic lipid-nucleic acid-delivery complexes
08/14/2003US20030153073 Expansion of T cells in vitro and expanded T cell populations
08/14/2003US20030152973 G-protein coupled receptor org3
08/14/2003US20030152970 Methods and compositions to treat pain and painful disorders using 577, 20739 or 57145
08/14/2003US20030152947 Methods for detecting and treating the early onset of aging-related conditions
08/14/2003US20030152651 Herbal composition for angina pectoris, method to prepare same and uses thereof
08/14/2003US20030152638 Injectable opioid partial agonist or opioid antagonist microparticle compositions and their use in reducing consumption of abused substances
08/14/2003US20030152628 Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in an immediate-release layer with levodopa ethyl ester in a controlled release core
08/14/2003US20030152626 Substance P antagonist; antidepressants; central nervous system disorders; respiratory system disorders
08/14/2003US20030152552 Synergistic mixture; viricides, antiproliferative agents, antiinflammatory agents; side effect reduction
08/14/2003US20030152520 5-Substituted-2-arylpyridines
08/14/2003CA2486446A1 Substituted fused pyrazolecarboxylic acid arylamides and related compounds
08/14/2003CA2483630A1 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations
08/14/2003CA2478423A1 Gamma secretase inhibitors
08/14/2003CA2476275A1 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate cns nerve regeneration
08/14/2003CA2476218A1 Therapeutic compounds
08/14/2003CA2476214A1 Proliferated cell lines and uses thereof
08/14/2003CA2475767A1 Opioid receptor active 4-(3-hydroxyphenyl) or 4-(3-alkoxyphenyl)-1,2,4-triazole compounds
08/14/2003CA2475637A1 Quinolinone derivatives for treating cell proliferation related disorders
08/14/2003CA2475329A1 Truncated aggrecanase molecules
08/14/2003CA2475247A1 Anti-pathogen treatments
08/14/2003CA2475209A1 Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
08/14/2003CA2475101A1 Recombinant bovine immunodeficiency virus based gene transfer system
08/14/2003CA2475093A1 Dihydro-thia-phenanthrene-carbonyl-guanidines, method for the production thereof, use thereof as a medicament or diagnostic reagent
08/14/2003CA2474974A1 Cytoprotective benzofuran derivatives
08/14/2003CA2474921A1 Pharmaceutical tablet
08/14/2003CA2474917A1 Granzyme b inhibitors
08/14/2003CA2474783A1 Pluripotent embryonic-like stem cells derived from teeth and uses thereof
08/14/2003CA2474748A1 Inhibitors of alpha l beta 2 integrin mediated cell adhesion
08/14/2003CA2474687A1 N-allyloxyethyl-1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocines and the use of thereof as medicaments
08/14/2003CA2474508A1 Ansamycins having improved pharmacological and biological properties
08/14/2003CA2474283A1 Amino acid sequences capable of facilitating penetration across a biological barrier
08/14/2003CA2474214A1 Novel aryl- and heteroarylpiperazines
08/14/2003CA2474186A1 Compositions and methods for restoring immune responsiveness in patients with immunological defects
08/14/2003CA2474168A1 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia
08/14/2003CA2473505A1 Novel bicyclic hydroxamates as inhibitors of histone deacetylase
08/14/2003CA2473459A1 Pyridineamido derivatives as inhibitors of monoamine oxidase (mao-b)
08/14/2003CA2473182A1 Compositions and methods for treatment of vitamin d deficiency
08/14/2003CA2471586A1 Tumor necrosis factor combined with interferon in demyelinating diseases
08/14/2003CA2469925A1 Carnitine in the treatment of geriatric depression
08/14/2003CA2466251A1 Therapeutic use of aziridino compounds
08/14/2003CA2450807A1 Non-myeloablative tolerogenic treatment with tyrphostins
08/13/2003EP1335202A1 Method for screening compounds being modulators of neuromediators
08/13/2003EP1334972A1 Non-peptide compounds affecting the action of gonadotropin-releasing hormone (GnRH)
08/13/2003EP1334718A1 Drug composition comprising dipeptydyl aldehyde derivative
08/13/2003EP1334201A2 Dna expression vectors
08/13/2003EP1334192A2 Cystoskeleton-associated proteins
08/13/2003EP1334178A1 Slo2 and slo4, novel potassium channel proteins from human brain
08/13/2003EP1334120A2 Modified clostridial neurotoxins with altered biological persistence
08/13/2003EP1334103A2 Methods for treatment of disease-induced peripheral neuropathy and related conditions
08/13/2003EP1334102A1 Bombesin receptor antagonists
08/13/2003EP1334100A1 Bombesin receptor antagonists
08/13/2003EP1334098A2 Amidoalkyl-piperidine and amidoalkyl-piperazine derivatives for treating of nervous systems disorders
08/13/2003EP1334091A2 Thioflavin derivatives and their use in diagnosis and therapy of alzheimer's disease
08/13/2003EP1334089A1 Quinoline derivatives as nk-3 and nk-2 antagonists
08/13/2003EP1334088A1 Quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
08/13/2003EP1334087A1 Cycloalkylfluorosulfonamide derivatives
08/13/2003EP1334086A1 Phenoxyphenyl alkane sulfonates
08/13/2003EP1334085A1 Sulfamides as gamma-secretase inhibitors
08/13/2003EP1334082A2 Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
08/13/2003EP1333863A2 Vector system for transducing th positive neurons
08/13/2003EP1333853A1 Growth factor complex
08/13/2003EP1333842A2 Use of cortisol-sequestering agents for the treatment of hypercortisolaemia related disorders
08/13/2003EP1333841A2 M. tuberculosis chaperonin 10 and uses thereof
08/13/2003EP1333840A2 M. tuberculosis chaperonin 60.1 and uses thereof
08/13/2003EP1333835A1 The use of selective noradrenaline reuptake inhibitors for the treatment of tension-type headache
08/13/2003EP1333833A2 Novel compounds
08/13/2003EP1333832A1 Novel uses of combined 5-ht1a agonists and serotonin reuptake inhibitors
08/13/2003EP1333828A2 Prevention of development of dyskinesias
08/13/2003EP1333827A2 Estrogen receptor modulators
08/13/2003EP1333821A2 Novel uses of combined selective dopamine d2 receptor antagonists and 5-ht1a receptor agonists
08/13/2003EP1333818A2 Titratable dosage transdermal delivery system
08/13/2003EP1333811A1 Liposomal formulation of mitoxantrone
08/13/2003EP1333809A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress
08/13/2003EP1333719A2 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
08/13/2003EP1256340B1 Improved transdermal therapeutic system for the treatment of Parkinson's disease
08/13/2003EP1222193B1 Imidazole derivatives as phosphodiesterase vii inhibitors
08/13/2003EP1216244B1 Benzisoxazolyl-, pyridoisoxazolyl- and benzthienyl-phenoxy derivatives useful as D4 antagonists
08/13/2003EP1165540B1 Tetrahydropyran derivatives and their use as therapeutic agents
08/13/2003EP1147108B1 Substituted nitrogen heterocyclic derivatives and pharmaceutical use thereof
08/13/2003EP1143942B1 Use of gaba-b receptor ligands for the manufacture of medicaments for the treatment of neurodegenerative diseases
08/13/2003EP1133296B1 Novel therapeutic application of nicergoline
08/13/2003EP1073658B1 Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
08/13/2003EP1034174B1 Azaring-ether derivatives and their use as nicotinic ach receptor modulators
08/13/2003EP0989859B1 Cns neuroregenerative compositions and methods of use
08/13/2003EP0979083B1 Use of 1-ar(alk)yl-imidazolin-2-one for treating anxiety and stress conditions
08/13/2003EP0976745B1 4-tetrahydropyridylpyrimidine derivatives
08/13/2003EP0956287B1 3-aryl-2-(1-substituted-4-piperidinyl)-1(1-di)oxo-3h-benzo d]-isothiazole derivatives, their preparation and their use as modulators of neurotransmitter function
08/13/2003EP0946539B1 Sulphonamide derivatives, process for their preparation, and their use as medicaments
08/13/2003EP0891328B1 Peptidyl compounds having mmp and tnf inhibitory activity
08/13/2003EP0814809B1 Aryl thioxanthines
08/13/2003EP0808313B1 Antipsychotic 4-(1h-indolyl-1-yl)-1-substituted piperidine derivatives
08/13/2003EP0667959B1 Methods for identifying inhibitors of the production of beta-amyloid peptide
08/13/2003EP0665843B1 Substituted quinuclidines as substance p antagonists
08/13/2003CN1436192A HMG-CoA reductase inhibitors and method
08/13/2003CN1436191A Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
08/13/2003CN1436188A 1,3,8-triaza-spiroÒÇö4,5ÒÇòdecan-4-one derivs. as neurokinin receptor antagonists
1 ... 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 ... 1833